Acorda Therapeutics (NASDAQ:ACOR) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACORFree Report) in a research note issued to investors on Wednesday. The brokerage issued a buy rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Trading Up 0.8 %

Shares of ACOR stock opened at $16.02 on Wednesday. Acorda Therapeutics has a 1 year low of $8.98 and a 1 year high of $24.20. The firm’s fifty day simple moving average is $14.27 and its 200 day simple moving average is $13.53. The firm has a market capitalization of $19.86 million, a P/E ratio of -0.94 and a beta of 1.43. The company has a current ratio of 1.59, a quick ratio of 1.21 and a debt-to-equity ratio of 3.07.

Acorda Therapeutics (NASDAQ:ACORGet Free Report) last announced its earnings results on Monday, November 13th. The biopharmaceutical company reported ($7.16) earnings per share (EPS) for the quarter. Acorda Therapeutics had a negative return on equity of 21.45% and a negative net margin of 14.35%. The company had revenue of $27.72 million for the quarter.

Institutional Investors Weigh In On Acorda Therapeutics

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new stake in Acorda Therapeutics during the third quarter worth $161,000. Deutsche Bank AG acquired a new stake in Acorda Therapeutics during the fourth quarter worth $26,000. Prudential Financial Inc. acquired a new stake in Acorda Therapeutics during the second quarter worth $28,000. Geode Capital Management LLC boosted its stake in Acorda Therapeutics by 44.8% during the fourth quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 20,948 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Acorda Therapeutics during the second quarter worth $68,000.

Acorda Therapeutics Company Profile

(Get Free Report)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.

Further Reading

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.